HHS awards $4.8B to Leidos for R&D Facilities Support, a sole-source contract nearing completion
Contract Overview
Contract Amount: $4,813,063,025 ($4.8B)
Contractor: Leidos Biomedical Research Inc
Awarding Agency: Department of Health and Human Services
Start Date: 2008-09-26
End Date: 2024-09-06
Contract Duration: 5,824 days
Daily Burn Rate: $826.4K/day
Competition Type: NOT COMPETED
Number of Offers Received: 1
Pricing Type: COST PLUS AWARD FEE
Sector: R&D
Official Description: TAS::75 0849::TAS OPER OF GOVT R&D GOCO FACILITIES
Place of Performance
Location: FREDERICK, FREDERICK County, MARYLAND, 21702
State: Maryland Government Spending
Plain-Language Summary
Department of Health and Human Services obligated $4.81 billion to LEIDOS BIOMEDICAL RESEARCH INC for work described as: TAS::75 0849::TAS OPER OF GOVT R&D GOCO FACILITIES Key points: 1. Significant long-term award to a single vendor for critical R&D infrastructure. 2. Sole-source nature raises questions about price discovery and potential for higher costs. 3. Contract duration and value indicate a high degree of reliance on Leidos. 4. Focus on facilities support for R&D suggests a specialized, potentially competitive market.
Value Assessment
Rating: questionable
The contract's Cost Plus Award Fee (CPAF) structure can incentivize performance but also lead to cost overruns if not managed tightly. Without competitive benchmarking, assessing the value for money is difficult.
Cost Per Unit: N/A
Competition Analysis
Competition Level: sole-source
This contract was not competed, indicating a sole-source award. This limits price discovery and may result in higher costs for taxpayers compared to a competitive process.
Taxpayer Impact: The lack of competition for a contract of this magnitude raises concerns about potential overspending and inefficient use of taxpayer funds.
Public Impact
Taxpayers are funding critical research facilities through a long-term, non-competitive agreement. The extended duration suggests a stable, but potentially less innovative, service provider. Potential for cost increases due to the absence of competitive pressure.
Waste & Efficiency Indicators
Waste Risk Score: 50 / 10
Warning Flags
- Sole-source award
- Long contract duration
- Cost-plus contract type
- Lack of small business participation
Positive Signals
- Supports critical R&D infrastructure
- Long-term stability for research operations
Sector Analysis
This contract falls under Facilities Support Services for Research and Development Government-Owned Contractor-Operated (GOCO) facilities. Spending in this niche sector is often driven by specific agency needs and can involve long-term, specialized service agreements.
Small Business Impact
The data indicates no small business participation in this contract. This suggests that the prime contractor, Leidos, is handling all aspects of the work, potentially missing opportunities to leverage specialized small business capabilities.
Oversight & Accountability
The long duration and sole-source nature of this contract warrant close oversight to ensure cost control and performance standards are met. Regular reviews of the award fee structure and contractor performance are crucial for accountability.
Related Government Programs
- Facilities Support Services
- Department of Health and Human Services Contracting
- National Institutes of Health Programs
Risk Flags
- Sole-source award limits competition and price discovery.
- Long contract duration increases risk of cost escalation and vendor lock-in.
- Cost-plus contract type can incentivize spending.
- Lack of small business participation may indicate missed opportunities.
- High contract value requires diligent oversight.
Tags
facilities-support-services, department-of-health-and-human-services, md, definitive-contract, billion-dollar
Frequently Asked Questions
What is this federal contract paying for?
Department of Health and Human Services awarded $4.81 billion to LEIDOS BIOMEDICAL RESEARCH INC. TAS::75 0849::TAS OPER OF GOVT R&D GOCO FACILITIES
Who is the contractor on this award?
The obligated recipient is LEIDOS BIOMEDICAL RESEARCH INC.
Which agency awarded this contract?
Awarding agency: Department of Health and Human Services (National Institutes of Health).
What is the total obligated amount?
The obligated amount is $4.81 billion.
What is the period of performance?
Start: 2008-09-26. End: 2024-09-06.
What was the justification for awarding this contract on a sole-source basis, and have alternative competitive strategies been considered for future renewals or similar contracts?
Sole-source awards are typically justified when only one responsible source can provide the required supplies or services. For R&D facilities, this might be due to unique expertise, proprietary technology, or existing infrastructure integration. Agencies should document this justification thoroughly and explore competitive options for future procurements to ensure best value and taxpayer savings.
How is the 'award fee' component structured, and what metrics are used to determine contractor performance and fee allocation to ensure alignment with government objectives?
The award fee structure is critical in a CPAF contract. It should clearly define performance objectives, metrics, and the associated fee ranges. The government must actively monitor performance against these metrics and objectively determine the fee, ensuring it reflects actual value received and incentivizes desired outcomes without excessive cost.
What is the government's strategy for managing potential cost growth over the contract's extended period, especially given the lack of competitive pressure?
Managing cost growth requires robust government oversight, including detailed cost analysis, regular performance reviews, and strict adherence to the contract's limitations on cost and fee. The government should proactively identify potential risks and implement mitigation strategies, potentially including negotiating cost-saving initiatives or exploring competitive re-procurement if feasible.
Industry Classification
NAICS: Administrative and Support and Waste Management and Remediation Services › Facilities Support Services › Facilities Support Services
Product/Service Code: OPERATION OF GOVT OWNED FACILITY › OPERATE GOVT OWNED BUILDINGS
Competition & Pricing
Extent Competed: NOT COMPETED
Solicitation Procedures: ONLY ONE SOURCE
Solicitation ID: N01CO8240192
Offers Received: 1
Pricing Type: COST PLUS AWARD FEE (R)
Evaluated Preference: NONE
Contractor Details
Parent Company: Leidos Holdings, Inc.
Address: MILLER DR BLDG 428, FREDERICK, MD, 21702
Business Categories: Category Business, Corporate Entity Not Tax Exempt, Not Designated a Small Business
Financial Breakdown
Contract Ceiling: $70,988,409,497
Exercised Options: $20,219,122,313
Current Obligation: $4,813,063,025
Actual Outlays: $4,445,108
Contract Characteristics
Multi-Year Contract: Yes
Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED
Cost or Pricing Data: NO
Timeline
Start Date: 2008-09-26
Current End Date: 2024-09-06
Potential End Date: 2024-09-06 00:00:00
Last Modified: 2024-09-10
More Contracts from Leidos Biomedical Research Inc
- Federal Contract — $2.4B (Department of Health and Human Services)
- NCI Operational Task Order — $1.8B (Department of Health and Human Services)
- NCI Operational Task Order — $437.4M (Department of Health and Human Services)
- NCI FY25 Operational Task Order — $398.9M (Department of Health and Human Services)
- NCI Operational Task Order, Fy26-Fy27 — $327.1M (Department of Health and Human Services)
Other Department of Health and Human Services Contracts
- Contact Center Operations (CCO) — $5.5B (Maximus Federal Services, Inc.)
- THE Purpose of This Contract IS to Provide the Full Complement of Services Necessary to Care for UC in ORR Custody Including Facilities Set-Up, Maintenance, and Support Internal and Perimeter (IF Applicable) Security, Direct Care and Supervision Inc — $3.5B (Rapid Deployment Inc)
- Contact Center Operations — $2.6B (Maximus Federal Services, Inc.)
- Federal Contract — $2.4B (Leidos Biomedical Research Inc)
- NCI Operational Task Order — $1.8B (Leidos Biomedical Research Inc)
View all Department of Health and Human Services contracts →